You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Last Updated: April 7, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for CC-223

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for CC-223?

CC-223 is an investigational drug.

There have been 5 clinical trials for CC-223. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, and Lymphoma. The leading clinical trial sponsors are Celgene Corporation and [disabled in preview].

There are thirty-four US patents protecting this investigational drug and three hundred and forty-four international patents.

Recent Clinical Trials for CC-223
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell LymphomaCelgene CorporationPhase 1
CC-223 and Ketoconazole Drug-Drug Interaction StudyCelgene CorporationPhase 1
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult SubjectsCelgene CorporationPhase 1

See all CC-223 clinical trials

Clinical Trial Summary for CC-223

Top disease conditions for CC-223
Top clinical trial sponsors for CC-223

See all CC-223 clinical trials

US Patents for CC-223

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CC-223   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
CC-223   Start Trial Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3- ,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
CC-223   Start Trial Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
CC-223   Start Trial Treatment of cancer with dihydropyrazino-pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CC-223

Drugname Country Document Number Estimated Expiration Related US Patent
CC-223 European Patent Office 3131552 2034-04-16   Start Trial
CC-223 Japan 2017514806 2034-04-16   Start Trial
CC-223 Japan 2019070012 2034-04-16   Start Trial
CC-223 New Zealand 629860 2034-04-16   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.